Capturing Cumulative Disease Burden in Chronic Kidney Disease Outcome Trials: Area Under the Curve and Restricted Mean Time in Favor of Treatment Beyond Conventional Time-to-First Analysis

2026-01-24

AI Summary

Traditional chronic kidney disease (CKD) outcome trials rely on time-to-first-event analyses, which disregard event severity and the duration of disease states, thereby failing to capture the cumulative therapeutic benefit comprehensively. This work proposes two novel approaches: an area-under-the-curve (AUC) metric based on ordinal severity scores and a restricted mean time under treatment advantage within a multi-state framework (RMT-IF). These methods uniquely integrate both event severity and time spent in distinct disease states into efficacy evaluation. By differentiating clinically meaningful events and quantifying overall improvement in disease trajectory, the proposed metrics offer a more efficient and interpretable assessment of renoprotective therapies in CKD trials.

Technology Category

• Knowledge Representation and Reasoning: Computational Complexity of Reasoning
• Search and Optimization: Mixed Discrete/Continuous Search
• Data Mining & Knowledge Management: Anomaly/Outlier Detection

Application Category

• Search and Retrieval-Augmented AI: Web evaluation methodologies and metrics
• User Modeling, Personalization and Recommendation: Metrics for user behavior and evaluating success
• Security and Privacy: Large-scale security measurements

Abstract

Chronic kidney disease (CKD) affects millions worldwide and progresses irreversibly through stages culminating in end-stage renal disease (ESRD) and death. Outcome trials in CKD traditionally employ time-to-first-event analyses using the Cox models. However, this approach has fundamental limitations for progressive diseases: it assigns equal weight to each composite endpoint component despite clear clinical hierarchy: an eGFR decline threshold receives the same weight as ESRD or death in the analysis, and it captures only the first occurrence while ignoring subsequent progression. Given CKD's gradual evolution over years, comprehensive treatment evaluation requires quantifying cumulative disease burden: integrating both event severity and time spent in each disease state. We propose two complementary approaches to better characterize treatment benefits by incorporating event severity and state occupancy: area under the curve (AUC) and restricted mean time in favor of treatment (RMT-IF). The AUC method assigns ordinal severity scores to disease states and calculates the area under the mean cumulative score curve, quantifying total event-free time lost. Treatment effects are expressed as AUC ratios or differences. The RMT-IF extends restricted mean survival time to multistate processes, measuring average time patients in the treatment arm spend in more favorable states versus the comparator. These methods better capture CKD's progressive nature where treatment benefits extend beyond first-event delay to overall disease trajectory modification. By discriminating between events of differing clinical importance and quantifying the complete disease course, these estimands offer alternative assessment frameworks for kidney-protective therapies, potentially improving efficiency and interpretability of future CKD outcome trials.

Problem

• chronic kidney disease
• cumulative disease burden
• time-to-first-event analysis
• composite endpoints
• disease progression

Innovation

• area under the curve
• restricted mean time in favor
• multistate modeling
• cumulative disease burden
• chronic kidney disease